Literature DB >> 25480341

New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?

Pankaj Kumar Garg1, Bhupendra Kumar Jain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25480341      PMCID： PMC4257748          DOI： 10.1634/theoncologist.2014-0263

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  Medical bankruptcy in the United States, 2007: results of a national study.

Authors:  David U Himmelstein; Deborah Thorne; Elizabeth Warren; Steffie Woolhandler
Journal:  Am J Med       Date:  2009-06-06       Impact factor: 4.965

3.  How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Authors:  Tito Fojo; Christine Grady
Journal:  J Natl Cancer Inst       Date:  2009-06-29       Impact factor: 13.506

4.  Quality of life in the trastuzumab for gastric cancer trial.

Authors:  Taroh Satoh; Yung-Jue Bang; Evgeny A Gotovkin; Yasuo Hamamoto; Yoon-Koo Kang; Vladimir M Moiseyenko; Atsushi Ohtsu; Eric Van Cutsem; Nedal Al-Sakaff; Alexa Urspruch; Julie Hill; Harald A Weber; Hyun-Cheol Chung
Journal:  Oncologist       Date:  2014-06-20

5.  Cancer drugs in the United States: Justum Pretium--the just price.

Authors:  Hagop M Kantarjian; Tito Fojo; Michael Mathisen; Leonard A Zwelling
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

6.  Insured yet vulnerable: out-of-pocket payments and India's poor.

Authors:  Renu Shahrawat; Krishna D Rao
Journal:  Health Policy Plan       Date:  2011-04-12       Impact factor: 3.344

Review 7.  Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Authors:  G Norman; S Rice; E Spackman; L Stirk; A Danso-Appiah; D Suh; S Palmer; A Eastwood
Journal:  Health Technol Assess       Date:  2011-05       Impact factor: 4.014

8.  Delivery of affordable and equitable cancer care in India.

Authors:  C S Pramesh; Rajendra A Badwe; Bibhuti B Borthakur; Madhu Chandra; Elluswami Hemanth Raj; T Kannan; Ashok Kalwar; Sanjay Kapoor; Hemant Malhotra; Sukdev Nayak; Goura K Rath; T G Sagar; Paul Sebastian; Rajiv Sarin; V Shanta; Suresh C Sharma; Shilin Shukla; Manavalan Vijayakumar; D K Vijaykumar; Ajay Aggarwal; Arnie Purushotham; Richard Sullivan
Journal:  Lancet Oncol       Date:  2014-04-11       Impact factor: 41.316
  8 in total
  3 in total

1.  Redefining the Treatment Endpoints in Oncology.

Authors:  Pallvi Kaul; Pankaj Kumar Garg
Journal:  Oncologist       Date:  2021-02-12

2.  ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.

Authors:  N I Cherny; R Sullivan; J Torode; M Saar; A Eniu
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

Review 3.  Hyperthermic Intraperitoneal Chemotherapy - Fading Perspective in the Light of Modern Systemic Chemotherapy?

Authors:  Pankaj Kumar Garg; Andreas Brandl; Beate Rau
Journal:  Visc Med       Date:  2018-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.